STAT3 and hepatocellular carcinoma: Furthermore, p-STAT3 (Tyr705) is a major kinase-independent target of sorafenib in hepatocellular carcinoma, and dephosphorylation at Tyr705 enhances the therapeutic efficacy of sorafenib in glioblastoma [61].